Supernus Pharmaceuticals Stock Jumps Over 20% on All-Stock Merger with Indivior

Supernus Pharmaceuticals (NASDAQ:SUPN) stock surged more than 20% in pre-market trading after the company announced a definitive agreement for an all-stock merger of equals with Indivior Pharmaceuticals. The deal immediately revalued Supernus shares toward the implied transaction price, causing the stock to climb to $53.88 ahead of the market open.

Details of the Merger

The transaction is structured as an all-stock, tax-free merger. According to the announcement, the key terms of the agreement are:

• Supernus stockholders will receive 1.5401 Indivior common shares for each Supernus share they own.
• Prior to the deal's closing, Indivior stockholders will receive a $1.0 billion aggregate special cash dividend, which will be funded by a new $650 million term loan.
• The combined entity will operate under the Supernus name and will continue to trade on the Nasdaq under the existing SUPN ticker.

Strategic Rationale and Market Impact

Ad

The merger is set to combine Supernus's neuroscience portfolio, which includes treatments for ADHD, Parkinson’s disease, and epilepsy, with Indivior’s established franchise in addiction treatment. This combination aims to create a more diversified specialty pharmaceutical company with a broader therapeutic reach.

The significant pre-market stock jump reflects investor approval of the deal's terms. The market's positive reception suggests the transaction is viewed as value-creating for Supernus shareholders, with the stock price adjusting to the valuation implied by the merger agreement.

Company Performance and Outlook

The deal comes at a time of strong performance for Supernus. The company recently reiterated its full-year 2026 revenue guidance of $840 million to $870 million following a robust first quarter. In Q1, Supernus reported revenues of $207.7 million, a 39% increase year-over-year, driven by a 56% rise in its growth products. This strong standalone performance was already recognized by Wall Street, with several firms holding Buy ratings on the stock.